Tamsulosin Hydrochloride
Product Images NDC 68071-2508

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-2508). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2508 1)

Label for Tamsulosin Hydrochloride 0.4 mg capsules from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 100 capsules and notes the product is Rx only. It includes NDC 68071-2508-1 and a warning to keep out of reach of children. Storage instructions recommend controlled temperature between 68-77°F. The label references distributed by 3 Rising Health LLC, Saddle Brook, NJ, and NuCare Pharmaceuticals, Inc., Orange, CA.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

Line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours after a single 0.4 mg capsule dose under fasted and fed conditions in eight subjects. Concentration (ng/mL) is plotted on the vertical axis, and time (hours) on the horizontal axis, with separate curves for fasted (dashed line) and fed (solid line) states.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' depicting treatment effects over 13 weeks. It compares mean symptom score changes for three groups: 0.8 mg dose, 0.4 mg dose, and placebo, showing symptom improvement trends across weeks with data points and sample sizes noted at intervals.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph showing mean change from baseline in total AUA symptom score over 13 weeks of treatment. The x-axis represents duration of treatment in weeks and the y-axis shows mean change scores. Three treatment groups are plotted: 0.8 mg and 0.4 mg doses, and placebo. Both doses show greater symptom score improvement over placebo throughout the study period.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' illustrating mean change over duration of treatment in weeks. It compares three treatment groups: 0.8 mg, 0.4 mg, and placebo, showing data points and mean changes in urine flow rate with sample sizes per timepoint.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

Line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in peak urine flow rate over 13 weeks of treatment. The x-axis represents duration of treatment in weeks, and the y-axis represents mean change in mL/Sec. Four treatment groups are plotted: 0.8 mg, 0.4 mg, placebo, and a control group, each represented by different markers connected by dashed lines. The 0.8 mg and 0.4 mg treatments show greater increases in peak urine flow rate compared to placebo over the treatment period.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure diagram of tamsulosin hydrochloride, showing its molecular components and bonds with an attached hydrochloride (HCl) group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.